CORRECTION

Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis

Neurol Neuroimmunol Neuroinflamm 2024;11:e200252. doi:10.1212/NXI.0000000000200252

In the Research Article "Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis" by Starvaggi Cucuzza et al.,[1] the first 2 sentences of the "B-Cell Data" section under the Methods should identify the total B cells and B memory cells as "($CD3^-CD19^+$)" and "($CD3^-CD19^+CD27\ldots$)," respectively. It should read as follows:

> *Total B-cell ($CD3^-CD19^+$) levels were assessed by flow cytometry before each rituximab infusion, as per clinical routine, at the Department of Clinical Immunology, Karolinska University Hospital. B memory cell ($CD3^-CD19^+CD27$+immunoglobulin D (IgD)-, $CD27^+IgD^+$, and $CD27^-IgD^-$) percentages were determined in patients with detectable B cells and converted to absolute numbers using the extracted data.*

The authors regret the error.

Reference

1. Starvaggi Cucuzza C, Longinetti E, Ruffin N, et al. Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis. *Neurol Neuroimmunol Neuroinflamm.* 2022;10(1):e200056. doi:10.1212/NXI.0000000000200056